Appendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
PRÉNUMBRA® Formulation Completed For Clinical Trial Use
CLINUVEL today announced the completion of manufacture of the first cGMP batch...
Read More
Chair's Letter
Melbourne, Australia, 09 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Results released today from a clinical study have shown that the drug...
Read More
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Technical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
NEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results from a clinical trial in a genetic DNA repair disorder show...
Read More